Drug Trial Radar · NCT04850118
A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP
Last checked: Nov 20, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
85
Actual
Start
Mar 14, 2024
Primary completion
Jun 30, 2026
Study completion Oct 31, 2031
Sponsor
- Lead sponsor
- Beacon TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 12 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501/laruparetigene zovaparvovec )) to an untreated control group in male participants with X-linked retinitis pigmentosa caused by RPGR mutations.
Conditions
- X-Linked Retinitis Pigmentosa
Interventions
rAAV2tYF-GRK1-hRPGRcoBiological
Adeno-associated virus vector expressing a human RPGR gene
ControlDrug
Untreated Control Group 3
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of participants with a ≥15 letter increase from baseline in LLVATime frame: Day 0 - Month 12
Locations
25 sites in 4 countries. Site status is shown where the registry gives one.
Retina Macula Institute of Arizona
Scottsdale, Arizona
Children's Hospital Los Angeles
Los Angeles, California
University of Florida Health Jacksonville, Department of Ophthalmology
Jacksonville, Florida
Bascom Palmer Eye Institute- University of Miami
Miami, Florida
Midwest Eye Institute (Retina Partners Midwest)
Carmel, Indiana
Wilmer Eye Institute at Johns Hopkins
Baltimore, Maryland
Ophthalmic Consultants of Boston
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Duke Eye Center
Durham, North Carolina
Cincinnati Eye Institute
Cincinnati, Ohio
Cole Eye Institute - Cleveland Clinic
Cleveland, Ohio
Casey Eye Institute, OHSU
Portland, Oregon
The Center for Advanced Retinal & Ocular Therapeutics University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania
Mid Atlantic Retina
Philadelphia, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania
Retina Consultants of Texas
Bellaire, Texas
Retina Foundation of the Southwest
Dallas, Texas
Baylor Eye Institute
Houston, Texas
Retina Consultants of San Antonio Texas
San Antonio, Texas
Sydney Eye Hospital
Sydney, New South Wales, Australia
Royal Victorian Eye & Ear Hospital
East Melbourne, Victoria, Australia
McGill University Health Centre - Glen Site
Montreal, Quebec, Canada
Moorfields Eye Hospital
London, United Kingdom
The Retina Clinic London, Institute of Ophthalmology, University College London
London, United Kingdom
Oxford Eye Hospital
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.